Displaying all 3 publications

Abstract:
Sort:
  1. So AD, Shah TA, Roach S, Ling Chee Y, Nachman KE
    J Law Med Ethics, 2015;43 Suppl 3:38-45.
    PMID: 26243242 DOI: 10.1111/jlme.12273
    The growing demand for animal products and the widespread use of antibiotics in bringing food animals to market have heightened concerns over cross-species transmission of drug resistance. Both the biology and emerging epidemiology strongly support the need for global coordination in stemming the generation and propagation of resistance, and the patchwork of global and country-level regulations still leaves significant gaps. More importantly, discussing such a framework opens the door to taking modular steps towards solving these challenges - for example, beginning among targeted parties rather than all countries, tying accountability to financial and technical support, or taxing antibiotic use in animals to deter low-value usage of these drugs. An international agreement would allow integrating surveillance data collection, monitoring and enforcement, research into antibiotic alternatives and more sustainable approaches to agriculture, technical assistance and capacity building, and financing under the umbrella of a One Health approach.
  2. Bibi A, Alam A, Fareed G, Ayaz M, Shah TA, Naz S, et al.
    Future Med Chem, 2026 Apr;18(8):881-893.
    PMID: 41808456 DOI: 10.1080/17568919.2026.2642677
    AIMS: Cyclooxygenase-2 (COX-2) is a key enzyme in pain perception and inflammatory cascade that make it an attractive target to develop safer anti-inflammatory agents.

    METHOD: In pursuit of potential anti-inflammatory agents, a new series based on α-naphthalene acetic acid has been synthesized through multi step reactions process. 1H-NMR and 13C-NMR spectroscopic techniques were used to confirm the structures of these derivatives.

    RESULTS: These compounds have been assessed for their in vitro COX-2 inhibitory activity, among them, compounds (4, 5, 13, and 3) exhibited excellent activity with IC50 value ranging from (IC50 = 0.36 ± 0.22 µM) to (IC50 = 0.43 ± 0.60 µM), while compounds (12, 11, and 14) showed significant activity.

    DISCUSSION: The molecular docking and density functional theory (DFT) analyses exposed that hydrazide derivatives based on α-naphthylene acetic acid displayed strong binding affinity for COX-2. Compound 13 revealed the highest binding energy of -9.771 kJ mol-1 and the lowest IC50 (0.43 µM) over π-π interactions and multiple hydrogen bonds. DFT study exposed that compound 13 influenced the highest softening and the smallest HOMO-LUMO energy gap, representing improved reactivity.

    CONCLUSION: In general, the computational as well as experimental consequences specify that compound 13 is a potent COX-2 inhibitor.

  3. Shah TA, Alam A, Zainab, Khan M, Elhenawy AA, Tajuddin AM, et al.
    Future Med Chem, 2025 Feb;17(3):313-328.
    PMID: 39882766 DOI: 10.1080/17568919.2025.2458452
    BACKGROUND: Due to the divers biological applications of Cu(II) complexes, we in this study reports the various Cu(II) complexes. The study aims to synthesize and assess new Cu(II) complexes as powerful β-glucuronidase inhibitors.

    METHODS: Five Schiff base ligands and their complexes were synthesized, characterized, and screened against β-glucuronidase inhibitory activity.

    RESULTS: In the series, compounds 3e, 3c, 2b, and 2c ascribed powerful inhibition ranging from (IC50  = 3.0 ± 0.7 µM) to (IC50  = 19.2 ± 0.8 µM). A precise and particular arrangement of atoms is suggested by the triclinic p-1 space group and the existence of a single molecule in an asymmetric unit, which are indispensable for the reactivity as well as the stability of the compounds. The analysis of the Hirshfeld surface provides information about the hydrogen intermolecular and π-π interactions. Based on molecular docking, binding potency increasing by complexation 3a-e compared to ligands 2a-e as well as reference Saccharic acid and uronic isofagomine inhibitor, suggesting that it may be a potent inhibitor of these receptors.

    CONCLUSION: The work recognizes latent active compounds for novel β-glucoronidase inhibitors, by further support these may be harnessed for the development of potent drugs.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links